46002-83-9

Basic information

• Product Name: 1-(2-METHOXY-4,6-DIMETHYLPYRIDIN-3-YL)METHANAMINE
• Synonyms: 1-(2-METHOXY-4,6-DIMETHYLPYRIDIN-3-YL)METHANAMINE;1-(2-methoxy-4,6-dimethylpyridin-3-yl)methanamine(SALTDATA: FREE);(2-Methoxy-4,6-diMethylpyridin-3-yl)MethanaMine;(2-methoxy-4,6-dimethylpyridin-3-yl)methanamine(WXC09787)
• CAS NO: 46002-83-9
• Molecular Formula: C₉H₁₄N₂O
• Molecular Weight: 166.22
• Mol File: 46002-83-9.mol

Chemical Properties

• Boiling Point: 267.6°C at 760 mmHg
• Flash Point: 115.7°C
• Appearance: /
• Density: 1.044g/cm³
• Vapor Pressure: 0.00806mmHg at 25°C
• Refractive Index: 1.529
• CAS DataBase Reference: 1-(2-METHOXY-4,6-DIMETHYLPYRIDIN-3-YL)METHANAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-METHOXY-4,6-DIMETHYLPYRIDIN-3-YL)METHANAMINE(46002-83-9)
• EPA Substance Registry System: 1-(2-METHOXY-4,6-DIMETHYLPYRIDIN-3-YL)METHANAMINE(46002-83-9)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 46002-83-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-Methoxy-4,6-dimethylpyridin-3-yl)methanamine is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of antihypertensive and antiarrhythmic drugs. Its unique chemical structure allows it to be incorporated into more complex molecules, enhancing the therapeutic potential of these medications.
Used in Medication Development:
1-(2-Methoxy-4,6-dimethylpyridin-3-yl)methanamine is utilized as a building block in the creation of various medications due to its important chemical and pharmacological properties. Its role in the synthesis process is crucial for the development of effective treatments for a range of health conditions, particularly those related to cardiovascular health.

InChI:InChI=1/C9H14N2O/c1-6-4-7(2)11-9(12-3)8(6)5-10/h4H,5,10H2,1-3H3

Upstream product

• 65515-39-1 3-cyano-4,6-dimethyl-2-methoxypyridine 
• 769-28-8 3-Cyano-4,6-dimethyl-2(1H)-pyridon 
• 14237-71-9 2-chloro-4,6-dimethylnicotinonitrile 

Downstream Products

• 1616290-46-0 methyl 3-bromo-6-(2-{[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]amino}ethoxy)-2-methylbenzoate 
• 1616290-33-5 methyl 2-(2-{[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]amino}ethoxy)-3-(propan-2-yloxy)benzoate 
• 1173081-96-3 (4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methylamine hydrochloride 

Relevant articles and documents

ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS

This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS

This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat

Posttranslational methylation of histones plays a critical role in gene regulation. Misregulation of histone methylation can lead to oncogenic transformation. Enhancer of Zeste homologue 2 (EZH2) methylates histone 3 at lysine 27 (H3K27) and abnormal methylation of this site is found in many cancers. Tazemetostat, an EHZ2 inhibitor in clinical development, has shown activity in both preclinical models of cancer as well as in patients with lymphoma or INI1-deficient solid tumors. Herein we report the structure-activity relationships from identification of an initial hit in a high-throughput screen through selection of tazemetostat for clinical development. The importance of several methyl groups to the potency of the inhibitors is highlighted as well as the importance of balancing pharmacokinetic properties with potency.

SUBSTITUTED BICYCLIC COMPOUNDS AS INHIBITORS OF EZH2

The present invention provides compounds of formula 1, isotopic forms, stereoisomers or tautomers thereof, or pharmaceutically acceptable salts, solvates, N-oxides, S-oxides and polymorphs thereof, and processes for their preparation. The invention further relates to pharmaceutical compositions containing said compounds and their use in the treatment of diseases or disorders mediated by EZH2 (enhancer of zeste homolog 2), particularly cancer.

ARYL AND HETEROARYL FUSED LACTAMS

This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Pyrazole compounds and their use as antidiabetes agents

The present invention provides a pyrazole compound that has liver glycogen phosphorylase inhibitory activity and is useful as a therapeutic or prophylactic agent for diabetes, the pyrazole compound represented by the following general formula (I): wherein Ring Q represents an aryl or heteroaromatic group, R1 represents a hydrogen atom, a halogen atom, a C1-6 alkyl group or a C1-6 alkoxy group, R2 represents a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group or an azido group, R3 represents a halogen atom, a hydroxyl group, a C1-6 alkyl group, a halo C1-6 alkyl group, a C1-6 alkoxy group, an azido group, an amino group, an acylamino group or a C1-6 alkylsulfonylamino group, R4 and R5 are identical with or different from each other and represent a hydrogen atom, a substituted or unsubstituted C1-6 alkyl group, a C3-8 cycloalkyl group, a substituted or unsubstituted saturated heterocyclic group, a substituted or unsubstituted aryl group, a C7-14 aralkyl group, a heteroaromatic group, or the like, or a pharmacologically acceptable salt thereof.